In addition, syringetin inhibited the production of M-CSF and RANKL and promoted the production of osteoprotegerin (OPG), a decoy receptor for RANKL, in osteoblasts stimulated by lung cancer cells, thereby blocking the AKT-mTOR pathway and suppressing osteoclast differentiation [43]. The gene discussed is TNFRSF11B; the disease is lung carcinoma.